Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
G. B. Migliori, R. Muetterlein, G. Sotgiu, G. De Iaco, K. Kliiman, O. Toungoussova, J. Ortmann, H. Hoffmann, E. Girardi, F. Lauria, C. Lange, TBNET Study Group (Tradate, Sassari, Sondalo, Cassano delle Murge, Rome, Italy; Parsberg, Bad Lippspringe, Gauti. Second-line injectables: are they essential to treat MDR/XDR-TB cases?. Eur Respir J 2008; 32: Suppl. 52, 1350

Member's Comments

No comment yet.

Related content which might interest you: Second- and third-line therapies: what are the best options? Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies Year: 2007 Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007 Failing a re-treatment regimen does not predict MDR/XDR tuberculosis: is “blind” treatment dangerous? Source: Eur Respir J 2011; 37: 1283-1285 Year: 2011 What happens to pneumocystis prophylaxis use when antiretroviral therapy is widely available? Source: Annual Congress 2012 - Viral infections and rare respiratory infections Year: 2012 Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use Source: Eur Respir J 2014; 43: 289-292 Year: 2004 Availability of PCR for second-line drugs in Europe Source: International Congress 2016 – Advances in tuberculosis diagnosis and monitoring of treatment Year: 2016 Availability of fixed-dose, child-friendly formulations of first-line tuberculosis drugs in Europe Source: Eur Respir J, 58 (3) 2101196; 10.1183/13993003.01196-2021 Year: 2021 Effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of multidrug resistant tuberculosis Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 Four-month regimens: are they feasible? Source: International Congress 2015 – Tuberculosis: short-course chemotherapy Year: 2015 Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes Source: Eur Respir J 2013; 42: 156-168 Year: 2013 Fixed-dose combination antituberculosis therapy: is the INH dose adapted for the Tunisianpopulation? Source: International Congress 2018 – Challenges in tuberculosis care Year: 2018 Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis? Source: Eur Respir J 2008; 31: 904-905 Year: 2008 Outcomes for multidrug-resistant tuberculosis patients with and without resistance to fluoroquinolones and second-line injectable drugs: A meta-analysis of individual patient data Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment Year: 2012 Antituberculosis fixed multi-dose combination and single drug therapy in active tuberculosis: What is the benefit? Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 MDR-TB management: what is new? Source: School Course 2012 - TB and M/XDR-TB: from clinical management to control and elimination Year: 2012 New anti-tuberculosis drugs and regimens: 2015 update Source: ERJ Open Res 2015; 1: 00010-2015 Year: 2015 Macrolides (alone or in combination) should be used as first-line empirical therapy of community-acquired pneumonia in children: myth or maxim? Source: Breathe, 17 (3) 210056; 10.1183/20734735.0056-2021 Year: 2021 Two major problems in TB patients today: MDR and the abandoned therapy Source: Annual Congress 2011 - Challenges in tuberculosis control Year: 2011 Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance Source: Eur Respir J 2012; 39: 802-804 Year: 2012